Discovery of GS-9669, a thumb site II non-nucleoside inhibitor of NS5B for the treatment of genotype 1 chronic hepatitis C infection.

Investigation of thiophene-2-carboxylic acid HCV NS5B site II inhibitors, guided by measurement of cell culture medium binding, revealed the structure-activity relationships for intrinsic cellular potency. The pharmacokinetic profile was enhanced through incorporation of heterocyclic ethers on the N-alkyl substituent. Hydroxyl groups were incorporated to modulate protein binding. Intrinsic potency was further improved through enantiospecific introduction of an olefin in the N-acyl motif, resulting in the discovery of the phase 2 clinical candidate GS-9669. The unexpected activity of this compound against the clinically relevant NS5B M423T mutant, relative to the wild type, was shown to arise from both the N-alkyl substituent and the N-acyl group.

[1]  O. Hucke,et al.  Molecular dynamics simulations and structure-based rational design lead to allosteric HCV NS5B polymerase thumb pocket 2 inhibitor with picomolar cellular replicon potency. , 2014, Journal of medicinal chemistry.

[2]  O. Hucke,et al.  Enantiomeric atropisomers inhibit HCV polymerase and/or HIV matrix: characterizing hindered bond rotations and target selectivity. , 2014, Journal of medicinal chemistry.

[3]  M. Manns,et al.  Novel therapies for hepatitis C — one pill fits all? , 2013, Nature Reviews Drug Discovery.

[4]  Monish Jain,et al.  Metabolically Stable tert-Butyl Replacement. , 2013, ACS medicinal chemistry letters.

[5]  C. Stedman,et al.  Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. , 2013, The New England journal of medicine.

[6]  T. Pilot‐Matias,et al.  Exploratory study of oral combination antiviral therapy for hepatitis C. , 2013, The New England journal of medicine.

[7]  S. Leavitt,et al.  Preclinical Characterization of GS-9669, a Thumb Site II Inhibitor of the Hepatitis C Virus NS5B Polymerase , 2012, Antimicrobial Agents and Chemotherapy.

[8]  B. Riedl,et al.  Discovery of substituted N-phenylbenzenesulphonamides as a novel class of non-nucleoside hepatitis C virus polymerase inhibitors. , 2012, Antiviral research.

[9]  Melanie H. Wong,et al.  Tri-substituted acylhydrazines as tertiary amide bioisosteres: HCV NS5B polymerase inhibitors. , 2012, Bioorganic & medicinal chemistry letters.

[10]  W. L. Jorgensen,et al.  Methyl effects on protein-ligand binding. , 2012, Journal of medicinal chemistry.

[11]  H. Dvory‐Sobol,et al.  1189 GS-9669, A NOVEL NS5B NON-NUCLEOTIDE SITE II INHIBITOR, DEMONSTRATES POTENT ANTIVIRAL ACTIVITY, FAVORABLE SAFETY PROFILE AND POTENTIAL FOR ONCE-DAILY DOSING , 2012 .

[12]  P. Troke,et al.  Antiviral activity of the hepatitis C virus polymerase inhibitor filibuvir in genotype 1–infected patients , 2011, Hepatology.

[13]  Amy D. Fung,et al.  Cyclic amide bioisosterism: strategic application to the design and synthesis of HCV NS5B polymerase inhibitors. , 2010, Bioorganic & medicinal chemistry letters.

[14]  A. Ray,et al.  HCV NS5B polymerase inhibitors. , 2010, Current opinion in drug discovery & development.

[15]  Huiling Yang,et al.  Novel Hepatitis C Virus Reporter Replicon Cell Lines Enable Efficient Antiviral Screening against Genotype 1a , 2010, Antimicrobial Agents and Chemotherapy.

[16]  T. Herbertz,et al.  The discovery and structure-activity relationships of pyrano[3,4-b]indole-based inhibitors of hepatitis C virus NS5B polymerase. , 2010, Bioorganic & medicinal chemistry letters.

[17]  E. H. Rydberg,et al.  Identification and biological evaluation of a series of 1H-benzo[de]isoquinoline-1,3(2H)-diones as hepatitis C virus NS5B polymerase inhibitors. , 2009, Journal of medicinal chemistry.

[18]  R. Larouche,et al.  940 SAFETY, TOLERABILITY AND PHARMACOKINETICS OF THE HCV POLYMERASE INHIBITOR VCH-222 FOLLOWING SINGLE DOSE ADMINISTRATION IN HEALTHY VOLUNTEERS AND ANTIVIRAL ACTIVITY IN HCV-INFECTED INDIVIDUALS , 2009 .

[19]  Hui Li,et al.  Discovery of (R)-6-cyclopentyl-6-(2-(2,6-diethylpyridin-4-yl)ethyl)-3-((5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl)-4-hydroxy-5,6-dihydropyran-2-one (PF-00868554) as a potent and orally available hepatitis C virus polymerase inhibitor. , 2009, Journal of medicinal chemistry.

[20]  Rajiv Chopra,et al.  Identification of anthranilic acid derivatives as a novel class of allosteric inhibitors of hepatitis C NS5B polymerase. , 2007, Journal of medicinal chemistry.

[21]  David Haigh,et al.  Optimization of novel acyl pyrrolidine inhibitors of hepatitis C virus RNA-dependent RNA polymerase leading to a development candidate. , 2007, Journal of medicinal chemistry.

[22]  Hui Li,et al.  Identification and structure-based optimization of novel dihydropyrones as potent HCV RNA polymerase inhibitors. , 2006, Bioorganic & medicinal chemistry letters.

[23]  George Burton,et al.  Identification of small molecule inhibitors of the hepatitis C virus RNA-dependent RNA polymerase from a pyrrolidine combinatorial mixture. , 2005, Bioorganic & medicinal chemistry letters.

[24]  Boris Feld,et al.  Discovery of pyrano[3,4-b]indoles as potent and selective HCV NS5B polymerase inhibitors. , 2004, Journal of medicinal chemistry.

[25]  Denis Labrecque,et al.  Discovery of thiophene-2-carboxylic acids as potent inhibitors of HCV NS5B polymerase and HCV subgenomic RNA replication. Part 1: Sulfonamides. , 2004, Bioorganic & medicinal chemistry letters.

[26]  Laval Chan and.  Discovery of Thiophene-2-carboxylic Acids as Potent Inhibitors of HCV NS5B Polymerase and HCV Subgenomic RNA Replication. Part 2. Tertiary Amides. , 2004 .

[27]  Meitian Wang,et al.  Non-nucleoside Analogue Inhibitors Bind to an Allosteric Site on HCV NS5B Polymerase , 2003, The Journal of Biological Chemistry.

[28]  Darius Bilimoria,et al.  Identification of N,N-disubstituted phenylalanines as a novel class of inhibitors of hepatitis C NS5B polymerase. , 2003, Journal of medicinal chemistry.

[29]  Z. Hong,et al.  In Vitro RNA Replication Directed by Replicase Complexes Isolated from the Subgenomic Replicon Cells of Hepatitis C Virus , 2003, Journal of Virology.

[30]  J. Silver,et al.  Replication of Subgenomic Hepatitis C Virus Rnas in a Hepatoma Cell Line , 1999 .

[31]  H. Bestmann,et al.  An Improved One-pot Procedure for the Synthesis of Alkynes from Aldehydes , 1996 .

[32]  D. Seyferth,et al.  Reactions of dimethylphosphono-substituted diazoalkanes. (MeO)2P(O)CR transfer to olefins and 1,3-dipolar additions of (MeO)2P(O)C(N2)R , 1971 .

[33]  J. Duan,et al.  Structure-based design of novel HCV NS 5 B thumb pocket 2 allosteric inhibitors with submicromolar gt 1 replicon potency : Discovery of a , 2013 .

[34]  A. Gopalsamy,et al.  The discovery and structure-activity relationships of pyrano[3,4-b]indole based inhibitors of hepatitis C virus NS5B polymerase. , 2010, Bioorganic & Medicinal Chemistry Letters.

[35]  T. Poll,et al.  Diastereoface-discriminative metal coordination in asymmetric synthesis: D-pantolactone as practical chiral auxiliary for Lewis acid catalyzed Diels-Alder reactions☆ , 1985 .